Logo

GSK’s Jemperli Receives the US FDA Approval as the 1L Treatment for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Share this
GSK

GSK’s Jemperli Receives the US FDA Approval as the 1L Treatment for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Shots:

  • The approval of Jemperli (dostarlimab-gxly) + carboplatin + paclitaxel, followed by Jemperli as monotx. for the treatment of adult patients with dMMR primary advanced or recurrent endometrial cancer
  • This approval is based on the interim analysis results from Part 1 of the P-III study (RUBY), which demonstrated a median duration of follow-up of ≥25mos. A significant and clinically meaningful benefit in PFS and a 71% reduction in the risk of disease progression or death. The trial continues to evaluate OS
  • Consistent safety and tolerability were seen over the monotherapies. The most common TEAEs were ≥20%. Also, the data were presented at ESMO and SGO 2023 and published in The New England Journal of Medicine.

Ref: Businesswire| Image: GSK

Related News:- GSK Reports the US FDA Acceptance of sBLA for Jemperli (dostarlimab) to Treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions